ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Syringaresinol Attenuates Aging-Associated Ferroptosis-Relevant Stress Through an HIF-1α-GPX4 Defense Axis.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ferroptosis contributes to aging-associated functional decline, yet compounds with robust organismal efficacy and defined upstream regulatory mechanisms remain limited. Here, we established a diethyl maleate (DEM)-induced glutathione depletion model in wild-type (N2) Caenorhabditis elegans as a survival-based screening platform and identified syringaresinol (Syr) as a leading hit from an in-house small-molecule library. In nematodes, Syr improved survival under DEM challenge, reduced lipid peroxidation, reactive oxygen species (ROS), and malondialdehyde levels, and alleviated age-associated oxidative lipid stress and iron imbalance during natural aging, accompanied by extended lifespan and improved healthspan-related phenotypes. In primary human foreskin fibroblasts, Syr conferred dose-dependent protection against RSL3- or erastin-induced ferroptosis, preserved cellular integrity, suppressed lipid peroxidation and ROS, and restored expression of GPX4, SLC7A11, and ferritin. In two senescence models, Syr also attenuated senescence-associated phenotypes and ferroptosis-related oxidative lipid stress, concomitant with recovery of GPX4 expression. Network-based prediction and functional perturbation identified HIF-1α as a candidate mediator of Syr-associated cytoprotection. HIF-1α knockdown weakened Syr-mediated protection and largely prevented GPX4 restoration, whereas GPX4 knockdown did not alter HIF-1α abundance. These findings support a functional HIF-1α-GPX4 defense axis in fibroblasts, while direct transcriptional regulation remains to be clarified. Overall, Syr attenuates ferroptosis-relevant oxidative lipid stress and aging-associated phenotypes in C. elegans and human fibroblast models, supporting further mechanistic and mammalian in vivo validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.